Literature DB >> 24777626

Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.

Kattareeya Kumthip1, Pattranuch Chusri, Chansom Pantip, Satawat Thongsawat, Amornrat O'Brien, Kenrad E Nelson, Niwat Maneekarn.   

Abstract

Different genotypes of hepatitis C virus (HCV) are circulating in different areas of the world. In Thailand, distribution of HCV genotypes has been investigated mostly in the central area while the information in other regions is limited. This study aimed to determine the HCV genotypes circulating in chronic hepatitis C patients in Chiang Mai, Thailand and to investigate the response of different HCV genotypes to pegylated interferon (PEG-IFN) and ribavirin (RBV) treatment. Patients infected chronically with HCV were treated with PEG-IFN/RBV based on the standard regimens for each HCV genotype and followed up the patients until the end of treatment and 6 months afterward. Out of 158 patients, three major HCV genotypes and eight subtypes were identified. Genotype 3 was the most predominant at 54.5%, followed by genotypes 1 (31%) and 6 (14.5%). Among subtypes, 3a was the most prevalent subtype (45%), followed by 1b (18.4%), 1a and 6f (each at 12.6%), 3b (9.5%), and 6a, 6i, 6n (each at 0.63%). Patients with genotype 3 showed higher rate of responding to the treatment at 80.2% compared to genotypes 1 (73.5%) and 6f (65%). Additionally, patients with genotype 6f showed higher rate of relapsing (25%) compared to genotypes 1 and 3 (14.3% and 16.3%, respectively). In conclusion, this study reported multiple HCV genotypes circulated in Thai patients and the response of different HCV genotypes to PEG-IFN/RBV treatment.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  HCV genotype; hepatitis C virus; pegylated interferon; ribavirin

Mesh:

Substances:

Year:  2014        PMID: 24777626     DOI: 10.1002/jmv.23962

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

1.  Analysis of mutations in the core and NS5A genes of hepatitis C virus in non-responder and relapser patients after treatment with Peg-IFN-α and ribavirin.

Authors:  Kattareeya Kumthip; Pattranuch Chusri; Chansom Pantip; Satawat Thongsawat; Amornrat O'Brien; Niwat Maneekarn
Journal:  Virusdisease       Date:  2016-01-18

2.  Hepatitis C virus infection among people who inject drugs in Bangkok, Thailand, 2005-2010.

Authors:  Michael Martin; Suphak Vanichseni; Wanna Leelawiwat; Rapeepan Anekvorapong; Boonyos Raengsakulrach; Thitima Cherdtrakulkiat; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Janet M McNicholl; Somyot Kittimunkong; Marcel E Curlin; Kachit Choopanya
Journal:  WHO South East Asia J Public Health       Date:  2019-04

3.  Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia.

Authors:  Rujipat Wasitthankasem; Sompong Vongpunsawad; Nipaporn Siripon; Chutima Suya; Phrutsada Chulothok; Kasemporn Chaiear; Pairaya Rujirojindakul; Sawan Kanjana; Apiradee Theamboonlers; Pisit Tangkijvanich; Yong Poovorawan
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.